On November 23, 2022, Xiling Lab successfully concluded a Pre-B round financing, securing nearly 100 million RMB. The financing round was a collaborative effort involving Chengdu International Biotwon No.1 Equity Investment Fund, Chengdu High-tech New Economy Venture Capital, Pengzhou Global Biomedical Technology Achievements Transformation Equity Investment Fund, CHTD Biomedical Park Management, as well as angel round investors CHDT Venture Capital and Shenzhen Jiuyuan Changqing Equity Investment Fund.
The funds will primarily support the IND application and Phase 1 clinical study of SMP-656, an ADC candidate drug developed by Xiling Lab, and the establishment of the XL-XDC technology platform. Dr. Jinkun Huang, the founder and CEO of Xiling Lab, expressed gratitude, stating, "We are immensely thankful to the investors for their support and recognition of Xiling Lab. Our mission is to revolutionize ADC cancer therapy, offering renewed hope to patients globally. Rooted in a profound understanding of chemistry and drug delivery, our ultimate goal is to pioneer groundbreaking ADC therapeutics capable of addressing and treating a spectrum of cancers."
